Kenjockety Biotechnology
Los Altos Hills, US · Founded 2017 · California LLC
Kenjockety Biotechnology develops bispecific antibodies (BsAbs) aimed at overcoming drug resistance in cancer patients. Its BASE platform pairs antibodies targeting efflux pumps with antibodies against known tumor-associated antigens to build therapeutics that target tumor cells more selectively than normal cells.
Founders & leadership
PD
Paul DeStefanoExecutive
WR
William Robert ArathoonExecutive
PN
Philippa NormanNamed on SEC filing
Board
DR
Daniel ReinerBoard director
Reported raises · per SEC filings
Form D private placements$4M disclosed across 1 round · 2017
▶$4MraisedMay 2017 · 5 investors · BiotechnologyRule 506(b)
▶$4MraisedMay 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul DeStefanoExecutive Officer
- Daniel ReinerDirector
- Philippa NormanExecutive Officer, Director
- William Robert ArathoonExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Apr 2017
- Incorporated
- Limited Liability Company, California, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Kenjockety Biotechnology do?
- Kenjockety Biotechnology develops bispecific antibodies (BsAbs) aimed at overcoming drug resistance in cancer patients. Its BASE platform pairs antibodies targeting efflux pumps with antibodies against known tumor-associated antigens to build therapeutics that target tumor cells more selectively than normal cells.
- How much funding has Kenjockety Biotechnology raised?
- Kenjockety Biotechnology has disclosed $4M raised across 1 round.
- Where is Kenjockety Biotechnology headquartered?
- Kenjockety Biotechnology is headquartered in Los Altos Hills, US.